profit from every $100 of sales.
$0$100
Maravai LifeSciences Holdings
$7.70-2.04% today
+136.9% in 1 year
1-year low $2.831-year high $9.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Maravai LifeSciences Holdings sold, what it kept, and what it did with the cash.
Sales went from $883 million in 2022 to $186 million in 2025, with -$131 million of profit last year.
SalesProfit
Maravai LifeSciences Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Maravai LifeSciences Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Maravai LifeSciences Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 883 | 289 | 259 | 186 | |
| 714 | 140 | 108 | 34 | |
| 566 | -28 | -73 | -129 | |
| 610 | 712 | -157 | -148 | |
| 220 | -119 | -145 | -131 | |
| 1.67 | -0.90 | -1.05 | -0.90 | |
| 80.9% | 48.5% | 41.8% | 18.3% | |
| 64.1% | -9.9% | -28.0% | -69.2% | |
| 24.9% | -41.2% | -55.9% | -70.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,282 | 1,487 | 1,008 | 771 |
| Cash | 632 | 575 | 322 | 217 |
| Total debt | 585 | 611 | 377 | 365 |
| Total liabilities | 1,377 | 698 | 431 | 398 |
| 545 | 417 | 325 | 212 | |
| 255 | 132 | 138 | 144 | |
| 40.0% | 51.0% | -24.1% | -28.5% | |
| 40.4% | -28.6% | -44.5% | -61.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 536 | 126 | 7 | -58 | |
| 17 | 66 | 30 | 13 | |
| 519 | 61 | -22 | -71 | |
| Dividends paid | – | – | – | – |
| 0 | – | – | – | |
| 19 | 35 | 49 | 30 |
Valuation
- –
- –
- –
- 3.3×
- 10.8×
- –
- –
- -3.5%
- -6.5%
- 0.0%
Profitability
- 18.3%
- -69.2%
- -70.4%
- -49.2%
- 6.5%
- -9.0%
- -44.7%
- -14.7%
- 6.7%
- 10.9%
Growth
- −40.5%
- –
- −218.7%
- –
- +6.0%
Financial health
- –
- 0.17
- 5.0%
- 1.7×
- 5.91
- 4.96
- 0.29
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 44%of 945
Bottom 6%of 868
Bottom 2%of 866
Bottom 24%of 985
What analysts expect
- Average price target
- $4.50
- Range
- $4.50 – $4.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.01 | -0.05 | +120.0% |
| Feb 25, 2026 | -0.04 | -0.07 | +42.9% |
| Nov 6, 2025 | -0.08 | -0.06 | −33.3% |
| Aug 11, 2025 | -0.08 | -0.06 | −33.3% |
| May 12, 2025 | -0.08 | -0.07 | −14.3% |
| Mar 18, 2025 | -0.06 | -0.03 | −100.0% |
| Nov 7, 2024 | -0.02 | -0.01 | −150.0% |
| Aug 7, 2024 | -0.08 | -0.04 | −100.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
18No pass
Benjamin Graham
39No pass
Philip Fisher
22No pass
Peter Lynch
27No pass
Joel Greenblatt
2No pass
Charlie Munger
22No pass
Terry Smith
17No pass
Questions about Maravai LifeSciences Holdings
Is Maravai LifeSciences Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Maravai LifeSciences Holdings AI analysis
What does Maravai LifeSciences Holdings do?
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. It is in Biotechnology.
Does Maravai LifeSciences Holdings pay a dividend?
No. Maravai LifeSciences Holdings does not pay a dividend at the moment.
Is Maravai LifeSciences Holdings stock halal?
Yes. Maravai LifeSciences Holdings passes our halal screen: its business is permitted and its debt is 18% of its market value, under the 30% limit. How we check
How has Maravai LifeSciences Holdings stock done over the past year?
Up 136.9% over the past twelve months, to $7.70. It traded between $2.83 and $9.00 and is 14.4% below its high.
Who are Maravai LifeSciences Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Maravai LifeSciences Holdings's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.